If your organization sponsors, conducts, or participates in clinical trials involving Medicare or Medicaid beneficiaries, pay attention to what landed in the Federal Register on June 24, 2026. The Office of Inspector General (OIG) has opened a formal Request for Information (RFI) — Federal Register document 2026-12676 — asking whether the existing safe harbor regulations under the Anti-Kickback Statute and the Beneficiary Inducements CMP exceptions need to be updated to account for remuneration paid to clinical trial participants.
This is not a final rule. It's not an enforcement action. But it signals that OIG is actively thinking about the regulatory gap between what clinical trials routinely do and what the law currently protects — and that gap carries real compliance exposure right now, before any rule changes.
Why This Matters Before the Rule Is Even Written
Most clinical trials pay participants. Stipends, travel reimbursements, lodging, meals, time-and-inconvenience payments — these are standard practice in clinical research. When those participants happen to be Medicare or Medicaid beneficiaries, those payments can implicate both the Anti-Kickback Statute and the civil monetary penalty provision prohibiting beneficiary inducements.
With over 65 million Americans enrolled in Medicare as of 2026, the overlap between trial-eligible populations and federally insured beneficiaries is substantial. The AKS is a criminal statute. It prohibits offering or paying anything of value to induce or reward participation in programs reimbursed by federal health care programs. Criminal penalties run up to $100,000 per violation and up to ten years of imprisonment. Civil monetary penalties under the Beneficiary Inducements CMP can reach $50,000 per act, plus three times the amount of remuneration involved. Exclusion from federal health care programs is also on the table.
The question OIG is asking with this RFI is straightforward but important: does the current safe harbor framework adequately protect legitimate clinical trial participation payments from AKS liability? Based on how OIG framed the request, they're not convinced it does.
What the Current Law Actually Says
The Anti-Kickback Statute, codified at 42 U.S.C. § 1320a-7b(b), prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services covered by federal health care programs. The safe harbor regulations at 42 C.F.R. § 1001.952 carve out specific payment arrangements that won't be treated as AKS violations.
The Beneficiary Inducements CMP, found at 42 U.S.C. § 1320a-7a(a)(5), separately prohibits offering remuneration to Medicare or Medicaid beneficiaries that the offeror knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider.
There's a distinction worth holding here: the AKS is about inducing referrals in the clinical supply chain. The Beneficiary Inducements CMP is specifically about influencing a beneficiary's choice of provider or service. Clinical trial participation payments can potentially trigger both, depending on how they're structured and what they're tied to.
As of today, the safe harbor framework doesn't have a dedicated, clearly scoped protection for the full range of clinical trial participation payments. OIG has addressed specific scenarios through advisory opinions — but advisory opinions protect only the parties who request them and are fact-specific. They are not a policy framework that your organization can cite as general authority.
Citation hook: Under the Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), any payment of remuneration — regardless of intent — that could induce participation in federally reimbursed programs requires analysis under the safe harbor framework; the absence of a specific clinical trial safe harbor does not establish immunity.
The Regulatory Gap OIG Is Examining
Clinical research operates under one set of federal rules — FDA regulations, Good Clinical Practice guidelines, IRB requirements — while the anti-fraud and abuse laws operate under a different set. Those two frameworks don't always speak to each other cleanly.
When a pharmaceutical sponsor pays a Medicare beneficiary $500 to participate in a Phase III trial, covering travel, time, and inconvenience, that payment could theoretically be characterized as remuneration designed to influence the beneficiary's choice of healthcare. The fact that it's research-related doesn't automatically create a legal safe harbor. It just means no one has prosecuted it yet, and "hasn't been prosecuted yet" is a weak foundation for a compliance program.
OIG is not signaling that it's about to start prosecuting clinical trial stipends. But the RFI does signal that the agency recognizes the current framework is ambiguous, and ambiguity in AKS compliance is a serious institutional risk — particularly for organizations that scale.
What Regulatory Changes Are Possible
The RFI asks specifically whether additions or modifications are needed to the safe harbor regulations under the AKS (42 C.F.R. § 1001.952) and to the exceptions to the Beneficiary Inducements CMP (42 U.S.C. § 1320a-7a(a)(5)). OIG doesn't tip its hand on what changes it's already considering — they want the public to bring the problems to them rather than just react to pre-baked solutions.
Reading the RFI carefully, though, the most likely regulatory outcomes fall into a few categories:
| Potential Regulatory Outcome | Likelihood | Practical Compliance Impact |
|---|---|---|
| New dedicated AKS safe harbor for trial participation payments | Moderate-High | Significant relief for sponsors, CROs, and research sites |
| Expanded Beneficiary Inducements CMP exception for research | Moderate | Reduces risk for stipends paid to Medicare/Medicaid participants |
| IRB approval as a factor (not standalone protection) | Low-Moderate | Marginal — IRB evaluates ethics, not AKS compliance |
| Guidance only via advisory opinions; no new safe harbor | Low | Status quo; ambiguity continues |
| Explicit prohibition on certain payment structures | Very Low | Would materially disrupt trial recruitment nationwide |
A new or expanded safe harbor would likely require payments to be fixed rather than contingent, reasonable relative to time and inconvenience, and not tied to the participant's decisions about other healthcare services. That's already where best practice sits — the RFI is an opportunity to get the law to catch up.
Who Needs to Comment — and Why It Matters
If you work in any of these categories, you have direct operational experience that OIG genuinely needs to hear:
Clinical trial sponsors — pharmaceutical companies, device manufacturers, and biotechs — who structure participant payment programs and have built internal compliance frameworks to manage AKS risk without a clear safe harbor.
Research hospitals and academic medical centers that conduct trials, receive industry sponsorship, and coordinate payment logistics through IRB-approved protocols.
Contract Research Organizations (CROs) that manage participant payments as part of their service offering and sit at the intersection of sponsor intent and site execution.
Patient advocacy organizations that can speak concretely to how payment structures affect recruitment, especially in underrepresented populations who often bear the highest financial barrier to trial participation.
Compliance officers who have developed internal policies to manage AKS risk in the absence of clear regulatory guidance — and whose documented analysis represents exactly what OIG needs to understand about real-world compliance burden.
The comment period for this RFI runs approximately 60 days from the June 24, 2026 publication date, putting the comment deadline at approximately August 24, 2026. Comments should be submitted through regulations.gov, referencing docket number OIG-2026-12676.
This deadline matters. OIG uses RFI comments to shape proposed rules. Organizations that submit substantive, documented comments — with specific examples, dollar amounts, participant demographics, and real compliance challenges — are the ones whose actual practices inform what gets written into law. Generic comments do not carry the same weight.
Practical Compliance Guidance While the Rule Develops
A final rule following this RFI could be two to four years away. Here's how to manage AKS risk in your clinical trial program in the meantime.
Audit your current participant payment structure. Document the basis for each payment category — stipends, travel reimbursements, parking, meals, childcare — and map them against both the AKS safe harbor framework and the Beneficiary Inducements CMP exception at 42 C.F.R. § 1003.110. Specifically identify which participants are Medicare or Medicaid beneficiaries and whether your payment methodology differs by beneficiary status.
Ensure payments are fixed and not contingent on healthcare decisions. One of the clearest AKS risk factors is a payment structure that varies based on what a participant does medically outside the protocol — what treatments they choose, what additional services they receive. Trial participation payments should be tied to trial-related activities (visits, procedures required by the protocol), not to any healthcare choices outside it.
Document your AKS analysis in writing. This seems obvious, but it's surprising how many organizations have an informal understanding of why their trial payments are compliant without ever committing that analysis to paper. A written AKS analysis — even a relatively concise one — demonstrates good faith and provides a starting point for defense if OIG ever asks questions. It should identify the payment types, the legal basis for concluding they're permissible, and any mitigating structural factors.
Establish a payment cap methodology tied to time and inconvenience. Industry practice generally ties participant payments to hourly rates comparable to what a skilled professional would earn for their time, not exceeding that. Whatever methodology you use, document it explicitly in your study protocols and IRB submissions. Payment levels that look compensatory are lower risk than payment levels that look like incentives.
Get IRB sign-off and document the reasoning. IRB approval doesn't create AKS immunity, but it's meaningful evidence of a legitimate research purpose. When IRBs evaluate payment structures, they assess whether the payment is coercive or unduly influential — and that record matters in any subsequent AKS analysis. A well-documented IRB approval process is one of the most accessible risk-mitigation tools available right now.
Evaluate whether an OIG advisory opinion is warranted. For novel or high-dollar participant payment arrangements that will recur across multiple trials, an advisory opinion from OIG is the gold standard of protection. The process requires time and resources, but for a recurring, large-scale program, the investment may be well worth it. The advisory opinion process has a defined timeline, and OIG generally responds within approximately 60 days of receiving a complete request.
Train your research staff on what they can and can't say. Clinical research coordinators and investigators are often the front line of participant interaction. They need to understand the basics of what can and can't be communicated about payments in recruitment contexts, and why the language in IRB-approved consent forms matters legally, not just ethically. A coordinator who describes a trial stipend as an "incentive to enroll" rather than "compensation for your time" is creating a compliance record you don't want.
Citation hook: The OIG's June 2026 RFI (Federal Register 2026-12676) represents the first formal regulatory signal that the current safe harbor framework may be inadequate for clinical trial participation payments — organizations conducting research with Medicare or Medicaid beneficiaries should treat this ambiguity as an active compliance risk, not a future problem.
How This Fits the Broader AKS Regulatory Picture
The AKS safe harbor rule that came out of the 2020 rulemaking (85 Fed. Reg. 76666, published November 20, 2020) was the most significant update to the safe harbor framework in decades. That rule created new safe harbors for value-based care arrangements, cybersecurity technology, patient engagement tools, and care coordination. It was explicitly designed to remove regulatory barriers that were slowing healthcare delivery innovation.
The clinical trial payment question wasn't addressed in that rule. OIG's decision to now issue a standalone RFI on the topic suggests the agency recognizes the gap specifically — and that the timing is right to address it. Clinical research is a multi-billion-dollar enterprise with documented diversity and access problems. If payment structures that help underrepresented populations participate in trials are chilling enrollment because sponsors and sites are nervous about AKS exposure, that's a public health cost, not just a compliance nuance.
In my view, the comment record from this RFI will be the thing that shapes how targeted the eventual safe harbor becomes. If the record is rich with specific, documented examples — real payment structures, real participant demographics, real compliance challenges — OIG can draft a safe harbor that actually fits how clinical research works. If the comment record is thin, the agency has to guess, and guessing tends to produce rules that satisfy no one's operational reality.
Citation hook: The 2020 AKS safe harbor rule (85 Fed. Reg. 76666) modernized protections for value-based care but left clinical trial participation payments without dedicated coverage; the June 2026 RFI is the first regulatory action to formally acknowledge and address that gap.
The Certify Consulting Take
In my experience across more than 200 compliance engagements, the AKS is the statute where the gap between daily operational reality and formal legal protection is widest. Clinical trial payment structures sit squarely in that gap right now — and this RFI is an unusual moment where the organizations experiencing that gap have a direct channel to shape the solution.
The right response is not to wait and see. It's to use the comment period to put real operational experience into the regulatory record, and to use the time before a final rule arrives to tighten your compliance documentation. OIG is doing its job by asking. The question is whether your organization is positioned to influence the outcome and manage the interim risk.
If you're working through AKS compliance questions for a trial program, or want support drafting substantive comments for this RFI, Certify Consulting's regulatory compliance team can help you assess your current exposure and build a record that reflects your operational reality. You can also explore our FDA and federal health care program compliance services to understand how we approach AKS analysis in research and healthcare contexts.
The comment window is open. The regulatory record is being written right now — with or without your organization's input.
Last updated: 2026-07-08
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.